An Open-Label Phase 2 Study of Oral CEP-701 in Patients With Asymptomatic Hormone-Refractory Cancer With Rising Prostate Specific Antigen
A serological PSA response is defined as a reduction from baseline PSA serum concentration
of at least 50%, which is confirmed by a second PSA value 28 or more days later.
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
|Johns Hopkins||Baltimore, Maryland 21231|